Imfinzi 120 mg Infusion 2.4 ml

Imfinzi 120 mg Infusion 2.4 ml is an anti-cancer medicine used in the treatment of unresectable, stage III non-small cell lung cancer (NSCLC). Imfinzi 120 mg Infusion 2.4 ml is also used in combination with tremelimumab-actl and platinum-based chemotherapy for treatment of metastatic NSCLC, in combination with etoposide and either carboplatin or cisplatin for treating extensive-stage small cell lung cancer, in combination with gemcitabine and cisplatin in treating metastatic biliary tract cancer, and in combination with tremelimumab-act in treatment of unresectable hepatocellular cancer.

Imfinzi 120 mg Infusion 2.4 ml contains Durvalumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the action of a programmed death ligand receptor-1 (PD-L1), thereby stopping the abnormal growth of cancer cells.

Imfinzi 120 mg Infusion 2.4 ml may cause certain side effects such as diarrhoea, nausea, vomiting, tiredness, itching, rash, headache, fever, shortness of breath, muscle/joint pain, abdominal pain, loss of appetite and injection site reactions. Inform your doctor if any of these side effects persist for longer. Imfinzi 120 mg Infusion 2.4 ml will be administered by an oncologist trained in administering anti-cancer agents. 

Avoid receiving Imfinzi 120 mg Infusion 2.4 ml and inform your doctor if you are allergic to it or any other components of it. This medicine is known to cause embryo-fetal toxicity. Hence, it is not recommended for use in pregnancy. Before taking Imfinzi 120 mg Infusion 2.4 ml, tell your doctor if you have/had liver or kidney disease, autoimmune disorders such as ulcerative colitis or Crohn's disease, a history of organ transplants, received an allogeneic stem cell transplant, or had radiation treatment to the chest, and myasthenia gravis. Avoid breastfeeding while taking this Imfinzi 120 mg Infusion 2.4 ml.

Imfinzi 120 mg Infusion 2.4 ml contains Durvalumab, which is used in the treatment of different types of cancers. It works by inhibiting the action of a programmed death ligand receptor-1 (PD-L1) that causes the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other body parts.

• Nausea
• Vomiting
• Diarrhoea
• Loss of appetite
• Weakness
• Muscle pain
• Cough
• Headache
• Fever
• Itching
• Rash
• Back pain
• Upper respiratory tract infections
• Injection site reactions

To treat your condition effectually, continue receiving Imfinzi 120 mg Infusion 2.4 ml for the period that your doctor has prescribed. Imfinzi 120 mg Infusion 2.4 ml may cause severe immune-mediated adverse reactions (IMAR) such as immune-mediated colitis, hepatitis, hepatotoxicity, nephritis, endocrinopathies, pneumonitis, cardiac problems, and dermatologic reactions. It may also cause infusion-related reactions in some patients. Therefore, caution should be exercised if you have/had liver or kidney disease, any history of organ transplant, gastrointestinal disorders, autoimmune disorders such as ulcerative colitis or Crohn’s disease, lung disease, heart problems, and breathing difficulty while receiving Imfinzi 120 mg Infusion 2.4 ml. This medicine may also cause severe infusion-related reactions. Hence, careful monitoring is recommended and discontinue the treatment if any severe infusion reactions occur. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 12 years of age as the safety and efficacy are not established. 

Drug-Drug Interactions: Imfinzi 120 mg Infusion 2.4 ml may have interaction with immunomodulator drugs (thalidomide), corticosteroids (prednisolone, methylprednisolone, prednisone), etc.

Drug-Food Interactions: Avoid alcohol consumption and smoking.

Dug-Disease Interactions: Tell your doctor if you have liver or kidney disease, heart problems, GI disorders, dermatitis, or a weak immune system before starting the treatment.

• THALIDOMIDE
• PREDNISOLONE
• PREDNISONE
• METHYLPREDNISOLONE

• Physical activity helps strengthen muscles, reduces fatigue, helps in weight loss, and gives strength. Gentle activities like 20-30 minutes of walking or swimming would be helpful.
• Maintain a healthy weight by performing regular low-strain exercises and eating healthy food.
• Getting adequate sleep as resting helps improve your health and mental ability and improves attention.
• De-stress yourself by meditating, reading books, taking a warm bubble bath, or listening to soothing music.
• Eat food rich in antioxidants such as berries, spinach, etc.
• Foods containing fibre help in better digestion. These include beans, peas, lentils, whole grains, nuts, and seeds.
• Avoid smoking and alcohol consumption.
• Maintain a healthy weight.

• Your doctor may suggest periodic liver function tests, kidney function tests, and lung function tests to monitor the function of the liver, kidney and lungs due to the use of Imfinzi 120 mg Infusion 2.4 ml.
• Using contraceptive pills while using Imfinzi 120 mg Infusion 2.4 ml to prevent pregnancy is advised.
• Thyroid function and adrenocorticotropic hormone levels will be monitored during treatment to avoid any life-threatening side effects.

Non-Small Cell Lung Cancer (NSCLC): It is the most common form of lung cancer, which occurs when cells that form the lining of the lung start growing uncontrollably. It is mostly seen in persons who smoke. Symptoms may include chest pain, weight loss, hoarseness, and difficulty breathing.

Hepatocellular carcinoma: It occurs when the cancer/ malignant cells grow out of control in the liver. This infects the liver, destroys the liver cells and affects the ability of the liver to work properly. Symptoms may include abdominal pain, loss of appetite, weight loss, and pale bowel motions.

Biliary tract cancer: Also known as bile duct cancer or Cholangiocarcinoma. It is a rare type of cancer in which the cancer cells grow abnormally in the epithelial cells lining the biliary tract. Symptoms may include abdominal pain, itching, fever, weight loss, changes in the colour of urine and stools, and jaundice.